Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Apr
16
Today In Oncology
Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
ALK-Positive NSCLC Adjuvant Alectinib vs Platinum-Based Chemotherapy
Cabozantinib in Advanced Adrenocortical Carcinoma
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside